Why Centene’s latest earnings and guidance update matter for investors

Centene (CNC) just posted second quarter results that showed revenue of US$53,579 million and net income of US$1,091 million, along with higher full year revenue and GAAP diluted EPS guidance.

The company also reported first half revenue of US$103,523 million and net income of US$2,632 million. This provides fresh context for assessing Centene stock after this guidance update.

Centene’s earnings beat and higher guidance have come alongside a strong year to date share price return of 48.92%. However, the 30 day share price return of 8.97% is lower and suggests momentum has cooled slightly after a strong 90 day share price return of 16.65%. Over a longer horizon, the 1 year total shareholder return of 140.14% contrasts with total shareholder returns that are slightly down over 3 and 5 years. This highlights how much of the recent gains are concentrated in the last year.

If Centene’s update has you rethinking healthcare exposure, this can be a useful moment to see what else is shaping the sector and review 41 healthcare AI stocks

After Centene’s sharp rebound and upgraded outlook, the debate now is simple. Is the recent surge already pricing in the good news, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 2.4% Undervalued

Centene’s most followed narrative pegs fair value at $63.78, which is slightly above the last close of $62.22. That gap is small, but the underlying assumptions are detailed.

Analysts are assuming Centene's revenue will grow by 4.0% annually over the next 3 years. Analysts assume that profit margins will increase from 3.6% today to 1.3% in 3 years time.

Want to see what sits behind that earnings reset for Centene? The narrative leans on a multi year shift in margins, revenue scale and future earnings power. The key driver is how much profit the business could be generating a few years from now, and what multiple that might command.

Result: Fair Value of $63.78 (UNDERVALUED)

However, the Centene narrative still hinges on uncertain Medicaid rate decisions and potential pressure from specialty drug costs that could squeeze margins if trends move against expectations.

Next Steps

Centene’s recent moves have sparked mixed reactions, and that is exactly when it makes sense to move fast and test the numbers for yourself. To weigh up both sides of the story, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Centene?

If Centene’s story has sharpened your focus, do not stop there. Fresh ideas often come from scanning outside your usual watchlist, and you do not want to miss that next lead.

• Spot opportunities with strong fundamentals by running the 55 high quality undervalued stocks before they land on everyone else's radar.
• Strengthen your core holdings by checking companies in the solid balance sheet and fundamentals stocks screener (45 results) that may better handle financial shocks.
• Broaden your watchlist with the screener containing 19 high quality undiscovered gems so you are not relying on the same crowded trades as everyone else.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.